Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trelegy Approval Boosts GSK's US Respiratory Business But Pressure Remains

Executive Summary

With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.

You may also be interested in...



GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US

Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.

Blow To AZ As FDA Rejects COPD Contender

Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.

Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab

The latest US drug development news and highlights from our Performance Tracker.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC099515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel